Silence Therapeutics Investor Relations Material
Latest events
Study Result
Silence Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Silence Therapeutics plc
Access all reports
Silence Therapeutics plc is a biotechnology company that focuses on the discovery and development of therapeutic molecules using RNA interference (RNAi) technology. The company’s proprietary mRNAi GOLD platform is designed to develop short interfering RNA (siRNA) therapies that target and silence specific genes associated with various diseases, particularly in the liver. Silence Therapeutics is involved in developing treatments for cardiovascular conditions, hematological disorders, and rare diseases. Their leading product candidates include Zerlasiran (SLN360) for cardiovascular disease and Divesiran (SLN124) for hematological conditions. Silence Therapeutics plc is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.
Key slides for Silence Therapeutics plc
Study Result
Silence Therapeutics plc
Study Result
Silence Therapeutics plc
Latest articles
Qualcomm: Quality Communication and Semiconductor Innovation
Founded in 1985, Qualcomm has transformed the digital communication industry with CDMA technology and its advanced semiconductor business.
13 Sep 2024
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
Novo Nordisk: The Danish Pharmaceutical Titan Revolutionizing Global Healthcare
Novo Nordisk's rise to becoming Europe's largest company, reshaping global healthcare and Denmark's economy.
5 Sep 2024
Ticker symbol
SLN
Country
🇺🇸 United States